Although the COVID-19 pandemic has contributed to the widespread, systematic adoption of decentralized elements in clinical trials, it is still early days for this new way of conducting research, which allows some or all study-related activities to be conduct in or near a patient’s home.
‘Decentralized Clinical Trials 2.0’ On The Horizon
The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, the Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead.
More from Pink Sheet Perspectives
More from Pink Sheet
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
• By
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
• By
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.